Berenberg analyst Luisa Hector raised the firm’s price target on Merck to $130 from $125 and keeps a Buy rating on the shares. The analyst sees further share price appreciation following the "significant de-risking" of the company’s cardiovascular pipeline.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck price target raised to $123 from $116 at Guggenheim
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
- Opko Health Surges as Merck Considers Deal
- Opko Health enters exclusive worldwide license agreement with Merck
- Sotatercept data supports bullish view of Merck cardio franchise, says Jefferies